Coronavirus Disease (COVID-19)

Infectious Diseases
3
Pipeline Programs
3
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Vaccine
133%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
TAK-019Phase 32 trials
Active Trials
NCT05299359Completed150Est. Oct 2023
NCT04712110Completed200Est. Mar 2022
M&
Merck & Co.RAHWAY, NJ
2 programs
2
MolnupiravirPhase 2/3Small Molecule4 trials
MolnupiravirPhase 2/3Small Molecule1 trial
Active Trials
NCT06615869Completed64Est. Mar 2023
NCT05386758Completed16Est. Mar 2023
NCT05386589Completed14Est. Jan 2023
+2 more trials
Moderna
ModernaCAMBRIDGE, MA
1 program
COVID-19 VaccineN/AVaccine1 trial
Active Trials
NCT04941144Completed8,538Est. Apr 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaTAK-019
Merck & Co.Molnupiravir
Merck & Co.Molnupiravir
TakedaTAK-019
Merck & Co.Molnupiravir
Merck & Co.Molnupiravir
Merck & Co.Molnupiravir
ModernaCOVID-19 Vaccine

Clinical Trials (8)

Total enrollment: 11,021 patients across 8 trials

NCT05299359TakedaTAK-019

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Start: Apr 2022Est. completion: Oct 2023150 patients
Phase 3Completed
NCT04575597Merck & Co.Molnupiravir

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

Start: Oct 2020Est. completion: May 20221,735 patients
Phase 2/3Completed
NCT04575584Merck & Co.Molnupiravir

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

Start: Oct 2020Est. completion: Aug 2021304 patients
Phase 2/3Terminated
NCT04712110TakedaTAK-019

A Study of TAK-019 in Healthy Japanese Adults (COVID-19)

Start: Feb 2021Est. completion: Mar 2022200 patients
Phase 1/2Completed
NCT06615869Merck & Co.Molnupiravir

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

Start: Jan 2023Est. completion: Mar 202364 patients
Phase 1Completed
NCT05386758Merck & Co.Molnupiravir

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

Start: Jun 2022Est. completion: Mar 202316 patients
Phase 1Completed
NCT05386589Merck & Co.Molnupiravir

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

Start: Jun 2022Est. completion: Jan 202314 patients
Phase 1Completed
NCT04941144ModernaCOVID-19 Vaccine

Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination

Start: Dec 2021Est. completion: Apr 20238,538 patients
N/ACompleted

Related Jobs in Infectious Diseases

Senior Recruiter

Invivyd
New Haven, CT (Northeast preferred)
5h ago
$120K - $160K/yr

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
12h ago
$179K - $237K/yr

First Line Sales Leader (Medan)

GSK
Indonesia - Sumatera Utara
Yesterday

General Worker

GSK
Pakistan - Sindh - Karachi
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (67% of programs)
3 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)